Jury says Apple owes Masimo $634M for patent infringement

A federal jury has ordered Apple to pay medical device maker Masimo $634 million for infringing a patent related to blood oxygen monitoring technology in the Apple Watch. While Apple intends to appeal, Masimo views the verdict as a significant victory for its intellectual property, underscoring the ongoing legal challenges and potential financial liabilities Apple faces concerning key features in its wearable devices, following a prior import ban on affected Apple Watch models.

Analysis

A federal jury has ordered Apple (AAPL) to pay medical device maker Masimo (MASI) $634 million for infringing a patent related to blood oxygen monitoring technology. This ruling specifically found that the Apple Watch's workout mode and heart rate notification features violated Masimo's intellectual property, marking a significant victory for Masimo in its ongoing efforts to protect its innovations.

Apple plans to appeal the verdict, asserting that the patent in question expired in 2022 and pertains to "historic patient monitoring technology." This legal setback follows a 2023 U.S. International Trade Commission (USITC) ruling that banned the import of Apple Watches with the infringing blood oxygen monitoring features, prompting Apple to introduce a redesigned feature that offloads calculations to the paired iPhone.

The $634 million judgment represents a notable financial liability for Apple, alongside the continued regulatory and legal challenges impacting a key feature of its wearable devices. While Apple previously won a statutory minimum payment of $250 in a countersuit against Masimo for design patent violations, the current verdict underscores the escalating stakes in this intellectual property dispute for both companies.

Key Decisions for Investors

• Investors in Apple (AAPL) should closely monitor the outcome of the appeal process, as the $634 million judgment could impact earnings and future product strategy, particularly concerning health features
• Investors in Masimo (MASI) should evaluate the sustainability of their intellectual property enforcement strategy and its potential to generate licensing revenue or further damages from competitors
• Consider the increasing litigation risk surrounding intellectual property in the technology and medical device sectors when assessing long-term investment viability